New Telehealth Platform for Sermorelin Therapy Launched

Written by

Sermorelin.com Unveils Telehealth Services for Sermorelin Treatment

Sheridan, United States – March 15, 2026 / Sermorelin.com /

Sermorelin.com has officially unveiled a new telehealth platform focused on sermorelin therapy, addressing the increasing interest among healthcare professionals in integrating sermorelin with GLP-1 protocols. This cutting-edge platform connects patients with licensed medical providers who can deliver sermorelin treatment under appropriate medical supervision. The launch coincides with research, including a 2025 PMC case series, that has demonstrated encouraging outcomes in fat loss while maintaining lean tissue, which has further sparked interest in sermorelin as a promising treatment alternative.

Mark Lombardi, CEO of Sermorelin.com, remarked, “Our aim is to establish a dedicated platform for sermorelin that operates under proper medical oversight. There is significant preliminary research on the combination of sermorelin and GLP-1, and we believe this pairing can improve patient outcomes.” The platform is designed to offer a safe and effective means for patients to access sermorelin therapy, ensuring they receive the essential guidance and support from qualified professionals.

Sermorelin is a 29-amino acid segment of growth hormone-releasing hormone (GHRH). It prompts the pituitary gland to produce and release growth hormone (GH), which is vital for numerous bodily functions, such as metabolism, muscle development, and overall health. A key benefit of sermorelin is its eligibility for 503A compounding, which allows for customized treatment plans tailored to the specific needs of individual patients.

Studies have indicated that sermorelin can result in notable enhancements in body composition. A study featured in the Journal of Clinical Endocrinology & Metabolism (JCEM) reported an average increase in lean mass of 1.26 kg among participants receiving sermorelin treatment. Furthermore, a meta-analysis published in the Annals of Internal Medicine indicated an average lean mass gain of 2.1 kg, further validating the effectiveness of sermorelin in facilitating muscle growth while assisting in fat reduction.

As with any medical intervention, it is crucial to consider possible side effects. Common side effects linked to sermorelin treatment may include reactions at the injection site, headaches, flushing, and nausea. It is important to highlight that the FDA has not removed sermorelin from the market for safety concerns since its approval in 2013, suggesting that it remains a safe option for patients when administered under medical supervision.

In conclusion, Mark Lombardi underscored the significance of sermorelin in the field of hormone optimization, stating, “Sermorelin is one of the most crucial tools in hormone optimization.” The introduction of the telehealth platform by Sermorelin.com marks a substantial advancement in enhancing access to this valuable treatment for patients looking to improve their health and well-being.

Sermorelin.com is the sole platform dedicated entirely to sermorelin peptides, providing physician-directed telehealth services. This unique concentration allows the company to deliver specialized care and support for patients interested in sermorelin therapy, ensuring they receive the highest standard of medical attention.

It is important to recognize that the information offered by Sermorelin.com is not meant to serve as medical advice. Patients seeking sermorelin treatment must acquire a prescription from a licensed healthcare provider. Additionally, while sermorelin has shown potential in various studies, it is not FDA-approved for all applications, and patients should consult their healthcare provider to determine the most suitable course of action for their individual circumstances.

Learn more on https://sermorelin.com/